Sun Pharmaceutical Industries Limited announced today it has, along with its subsidiaries, executed a settlement agreement with MedImmune, stipulating the dismissal of the lawsuits filed in the United States District Court for the District of Maryland regarding the submission of an Abbreviated New Drug Application (ANDA) for a generic version of Ethyol.

Under the settlement agreement, MedImmune interalia grants Sun Pharma a license to certain patents, permitting Sun Pharma to continue marketing the generic version of Ethyol in the United States. The settlement resolves the entirety of the litigations between the parties.

The scrip of the company today settled the day at Rs 1177 on BSE. The counter has made 52-week-high and low of Rs 1600 and Rs 953 respectively.